unit state go sg websit
result guidanc get boost us tax reform
upsid tp
nc chang
yesterday report sale line expect
ep benefit lower tax rate due us reform
guidanc line market expect sale better ep
reason tax guidanc initi expect
increas estim reflect new tax guidanc push
tp hold reiter
group sale line expect better earn thank lower tax rate sale
grew currenc portfolio adjust line consensu
sg sale new cancer product ibranc breast miss consensu
due one-off price adjust europ order gain better access accord
compani novartiss kisqali direct competitor launch play role view xeljanz
rheumatoid arthriti bit better expect like enbrel anti-tnf vaccin
prevnar tail product lipitor celebrex perform better expect
adjust ep consensu due mainli lower tax rate
vs despit softer oper profit due higher cog
better-than-expect guidanc help lower tax initi estim
pfizer guidanc line consensu sale better ep thank
lower tax rate sale stand low end rang non-gaap
ep new estim line tax rate vs
tax reform compani record repatri tax liabil payabl us
treasuri within eight year vein us pharma compani
commit invest us notabl manufactur capit
project within five year call mani question ask price
pressur ibranc europ drug super-blockbust potenti breast cancer
meaning contributor growth sale beyond
sustain tax rate manag confid pipelin improv
new product emerg cancer inflamm vaccin remain option
hold reiter compani attract new product cancer inflamm
think suffici re-energ top line low single-digit
growth vs sector group trade discount peer
price-to-earnings below-sector growth ep compound-annual-growth-rate vs
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
simplifi main product
sell inform administr
net incom attribut pfizer inc
confer call feedback tax rate ibranc take centr stage
tax rate call lot question ask sustain guid
tax rate manag say sustain
ibranc breast cancer despit price cut record compani remain
confid still access drug patient necessarili
posit read-across competitor novarti lilli made
effort lock market continu benefit first-entr statu good
safeti databas avail sinc launch us accord compani
patient treat europ drug first launch vs
us suggest well accept underli growth volum remain robust
despit price cut qoq
us price environ follow announc yesterday amazon berkshir
hathaway jpmorgan form healthcar compani cut cost us employe
manag said see posit industri better access afford
medicin posit innov compani end day pfizer ceo
stress pharma industri pressur decad compani
doesnt see situat today materi differ five ten year ago pharma
compani must constant dialogu payor valu drug base
fact emot aspect
view news amazon other unsurpris us healthcar system
lack transpar recent increas rebat pharma compani health
insur averag past five year realli benefit
patient thu view news neg us health insur
innov pharma compani howev pressur like persist pharma compani
presenc area drug well differenti fierc
competit limit innov diabet novo sanofi though
market expect lower latter danish compani respiratori gsk
immuno oncolog found tone still bullish bavencio
avelumab partner merckkgaa clinic develop programm
base three pillar monotherapi multipl combo idea turn cold tumor
hot tumor better abl respond immun oncolog treatment
biosimilar tail portfolio compani also quit optimist abil deliv
strong growth busi current benefit success inflectra
remicad togeth emerg product growth drive tail portfolio
call essenti health back growth come year still
interestingli manag stress believ impact gener portfolio
decreas time current less beyond howev
given size compani remain difficult grow busi note potenti
break-up longer agenda hidden valu within compani
keep togeth innov tail portfolio accord manag
adjust earn estim follow result mainli reflect lower tax rate
valuat tp increas vs
part
averag pharma premium innov
vaccin consum discount matur portfolio
tp deriv averag sum-of-th part sotp valuat dcf
roll forward sotp valuat estim differ oper margin
subdivis appli premium vs pharma sector multipl vaccin
premium consum divis vs previous also appli
discount matur portfolio vs discount dcf use wacc
long-term adjust oper margin vs perpetu growth
new york mellon corp
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet jan cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan seoul warsaw
averag sotp averag ev/ebita pharma multipl appli estim ebita subdivis
premium vs sector reflect growth profil dcf lt growth lt ebita margin
downsid risk faster eros establish product high singl digit impact ebit stronger biosimilar impact enbrel low
mid singl digit impact tougher ibranc competit landscap breast cancer low singl digit impact upsid risk stronger success
late stage pipelin mid singl digit impact
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
equiti rate dispers relationship
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assum entir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind morgan
stanley capit intern index servic mark affili similar languag may
provid approv advanc
sg act co-manag jpmorgan bond issu
sg act co-manag jp morgan bond issu
sg act co-manag jp morgan co bond issu
sg act co-manag jp morgan bond issu
